NCT00165230View on ClinicalTrials.gov

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Neuroendocrine Tumor
Interventions
DRUG

Thalidomide

DRUG

Temodar

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconness Medical Center, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00165230 - Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter